
    
      The study duration for each participant will be a total of minimum 29 weeks and up to 41
      weeks. This includes 4 weeks +/-1 week screening period, 24 weeks of treatment period and a
      follow-up period up to 12 weeks or until the patients switch to commercialized dupilumab (or
      other biologic products), whatever comes first.
    
  